David Wallace

TL;DR: Together, data show that MCD inhibitors, which increase myocardial malonyl CoA levels, decrease fatty acid oxidation and accelerate glucose oxidation in both ex vivo rat hearts and in vivo pig hearts, improve cardiac function during and after ischemia, suggesting that pharmacological inhibition of MCD may be a novel approach to treating ischemic heart disease.

TL;DR: Various derivatives were prepared surrounding the coumarin core structure to optimize the in vitro inhibitory activity of TNF-α production by human peripheral blood mononuclear cells (hPBMC), stimulated by bacterial lipopolysaccharide (LPS).

TL;DR: Demonstration of in vivo efficacy of methyl 5-(N-(2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate in a pig ischemia model indicated that MCD inhibitors may be useful for treating ischemic heart diseases.

TL;DR: In this article, the authors proposed a method for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

TL;DR: In this article, the authors proposed novel compounds composition capable of inhibiting TNFα and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.